NASDAQ:OMER - Omeros Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $15.33 -0.12 (-0.78 %) (As of 10/19/2018 01:01 AM ET)Previous Close$15.45Today's Range$15.06 - $15.6552-Week Range$8.36 - $27.00Volume355,600 shsAverage Volume1.03 million shsMarket Capitalization$1.19 billionP/E Ratio-19.35Dividend YieldN/ABeta3.49 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington. Receive OMER News and Ratings via Email Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:OMER CUSIP68214310 Webwww.omeros.com Phone206-676-5000 Debt Debt-to-Equity Ratio-2.31 Current Ratio3.95 Quick Ratio3.94 Price-To-Earnings Trailing P/E Ratio-19.35 Forward P/E Ratio-6.18 P/E GrowthN/A Sales & Book Value Annual Sales$64.83 million Price / Sales11.48 Cash FlowN/A Price / CashN/A Book Value($0.06) per share Price / Book-255.50 Profitability EPS (Most Recent Fiscal Year)($0.79) Net Income$-53,480,000.00 Net Margins-227.06% Return on EquityN/A Return on Assets-64.21% Miscellaneous Employees173 Outstanding Shares48,560,000Market Cap$1.19 billion Omeros (NASDAQ:OMER) Frequently Asked Questions What is Omeros' stock symbol? Omeros trades on the NASDAQ under the ticker symbol "OMER." How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.66) by $0.04. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analysts' expectations of $1.84 million. The business's revenue for the quarter was down 90.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.33) earnings per share. View Omeros' Earnings History. When is Omeros' next earnings date? Omeros is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Omeros. What price target have analysts set for OMER? 9 brokerages have issued 1 year target prices for Omeros' stock. Their forecasts range from $4.00 to $75.00. On average, they expect Omeros' stock price to reach $27.8763 in the next twelve months. This suggests a possible upside of 81.8% from the stock's current price. View Analyst Price Targets for Omeros. What is the consensus analysts' recommendation for Omeros? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Omeros. What are Wall Street analysts saying about Omeros stock? Here are some recent quotes from research analysts about Omeros stock: 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (10/9/2018) 2. Maxim Group analysts commented, "Omeros announced that the European Commission has granted Transplant (HSCT). This is the second EU orphan designation for OMS721, the first being IgA Nephropathy, note that the FDA has granted orphan designations for both aforementioned indications." (8/28/2018) 3. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We ascribe a total firm value of roughly $2B to Omeros based on OMIDRIA ($806M) and OMS721 ($1.2B). This translates into a target of $34.00 per share, based on 60M fully-diluted shares outstanding as of end-2Q 2019. Risks include: (1) trial delays; (2) adverse clinical results; (3) inability to obtain approval for OMS721 and other candidates; (4) inability to achieve additional market traction with OMIDRIA; and (5) earlier-than-anticipated introduction of OMIDRIA generics in the U.S." (8/6/2018) Who are some of Omeros' key competitors? Some companies that are related to Omeros include Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Endo International (ENDP), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Madrigal Pharmaceuticals (MDGL), Horizon Pharma (HZNP), Array Biopharma (ARRY), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND) and Ironwood Pharmaceuticals (IRWD). Who are Omeros' key executives? Omeros' management team includes the folowing people: Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 59)Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 60)Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 58)Dr. Pamela Pierce Palmer, Co-Founder (Age 55)Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 61) Who are Omeros' major shareholders? Omeros' stock is owned by a number of of institutional and retail investors. Top institutional investors include Nwam LLC (0.06%), Fox Run Management L.L.C. (0.04%) and Mesirow Financial Investment Management Inc. (0.03%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros. Which institutional investors are selling Omeros stock? OMER stock was sold by a variety of institutional investors in the last quarter, including Mesirow Financial Investment Management Inc. and Nwam LLC. Company insiders that have sold Omeros company stock in the last year include Marcia S Kelbon and Michael A Jacobsen. View Insider Buying and Selling for Omeros. Which institutional investors are buying Omeros stock? OMER stock was bought by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. View Insider Buying and Selling for Omeros. How do I buy shares of Omeros? Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Omeros' stock price today? One share of OMER stock can currently be purchased for approximately $15.33. How big of a company is Omeros? Omeros has a market capitalization of $1.19 billion and generates $64.83 million in revenue each year. The biopharmaceutical company earns $-53,480,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Omeros employs 173 workers across the globe. What is Omeros' official website? The official website for Omeros is http://www.omeros.com. How can I contact Omeros? Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000. MarketBeat Community Rating for Omeros (NASDAQ OMER)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 520 (Vote Outperform)Underperform Votes: 301 (Vote Underperform)Total Votes: 821MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/19/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?